T6	Exp 114 118	that
T7	Exp 268 273	which
T8	Exp 274 278	both
T9	Exp 386 408	the asymptomatic phase
T10	Exp 310 322	both viruses
T11	Exp 586 590	that
T12	Exp 470 487	The latent phases
T13	Exp 636 644	the case
T14	Exp 655 690	the transcription factor NF-kappa B
T15	Exp 876 878	we
T16	Exp 891 895	that
T17	Exp 993 1011	the HIV-2 enhancer
T18	Exp 863 874	this report
T19	Exp 1050 1054	that
T20	Exp 1055 1080	these Elf-1 binding sites
T21	Exp 1265 1269	that
T22	Exp 1204 1227	the only factor present
T23	Exp 1279 1290	these sites
T24	Exp 1377 1381	that
T25	Exp 1409 1454	the T-cell-receptor-mediated trans activation
T26	Exp 1522 1542	the clinical spectra
T27	Exp 1616 1626	the design
T28	Exp 1481 1494	These results
R7	Coref Anaphora:T6 Antecedent:T29
R8	Coref Anaphora:T7 Antecedent:T30
R9	Coref Anaphora:T11 Antecedent:T31
R10	Coref Anaphora:T22 Antecedent:T4
R11	Coref Anaphora:T21 Antecedent:T32
R12	Coref Anaphora:T24 Antecedent:T33
T1	Protein 42 47	Elf-1
T2	Protein 938 943	Elf-1
T3	Protein 1061 1066	Elf-1
T4	Protein 1195 1200	Elf-1
T5	Protein 1339 1344	Elf-1
T29	Exp 92 113	2 regulatory elements
T30	Exp 247 267	related retroviruses
T31	Exp 576 585	a process
T32	Exp 1231 1264	activated T-cell nuclear extracts
T33	Exp 1348 1376	a novel transcription factor
